High Growth Immunoassay Tests: Trends, Technologies, and Market Opportunities, 2026

Immunoassays remain a foundational pillar of the in vitro diagnostics (IVD) landscape, underpinning a broad range of clinical testing applications despite the maturity of many platforms. Their continued relevance reflects both their versatility across disease areas and the steady pace of technological refinement that has sustained growth and clinical adoption over time. This Kalorama Information report, High‑Growth Immunoassay Tests: Trends, Technologies, and Market Opportunities, 2026, examines the current and evolving role of immunoassays across centralized laboratory and point of care (POC) settings, highlighting why the segment remains strategically important for diagnostic manufacturers and healthcare stakeholders.

A Market Defined by Breadth and Evolution

Immunoassays encompass two core segments: high volume testing performed in centralized laboratories for screening, diagnosis, and patient monitoring, and rapid or point of care formats used for similar clinical purposes in decentralized settings. Across both segments, immunoassays support the detection of a wide array of analytes, including proteins, antibodies, hormones, and drugs. While many assays and platforms are well established, ongoing improvements in sensitivity, reliability, and automation continue to reinforce their clinical value.

Innovation Beyond Maturity: AI Driving the Next Phase of Immunoassays

Recent developments in immunoassay technology are reshaping what has traditionally been viewed as a mature market. Key innovation themes include expanded multiplexing capabilities, platform miniaturization to support point of care deployment, and the development of assays targeting novel biomarkers. Because artificial intelligence (AI) is driving much of the technology based growth, this report offers insights into key AI trends wherever relevant. AI is increasingly influencing immunoassay development and use by enabling predictive biomarker discovery, automating complex data interpretation, accelerating assay optimization, and supporting more sophisticated multi analyte detection strategies.

Scope of Analysis

This report provides a global assessment of immunoassay technologies across centralized laboratory systems and point of care formats, including immunochromatographic and lateral flow tests. Coverage emphasizes developed regions while also recognizing the critical role immunoassays play in expanding diagnostic access in settings with limited laboratory infrastructure. Market analysis is based on manufacturer revenues, reflecting testing volumes and utilization rather than downstream pricing or reimbursement dynamics.

Research Approach

Kalorama Information’s analysis is grounded in a rigorous combination of secondary research and primary industry engagement. Secondary research drew from a broad range of public and proprietary sources to establish market context and competitive positioning. These findings were validated and expanded through extensive interviews with industry executives, product managers, healthcare providers, consultants, and other stakeholders. All estimates were cross checked and triangulated to ensure consistency and reliability, with forecasts informed by historical trends, technological innovation, and global market expansion.

Strategic Relevance

As immunoassay technologies continue to evolve, the market reflects a balance between entrenched clinical reliance and emerging opportunities for differentiation—particularly as AI enabled tools reshape development pipelines and diagnostic workflows. This report focuses on the most relevant recent developments, streamlining legacy considerations where appropriate, and provides senior decision makers with a clear, current view of where immunoassays stand and where future growth and innovation are most likely to emerge.

Please Note: Single user allows for up to 3 users for this report. Show more